Nexalin Technology (NXL) announced the appointment of Dr. Robert Rothstein to its Scientific Advisory Board. In anticipation of the Company’s new FDA submissions, Dr. Rothstein will support Nexalin’s preparation of its Q-submission for a meeting with the FDA later this year. Dr. Rothstein has served in senior roles at prestigious institutions including the University of Chicago, Harbor/UCLA Medical Center, and Suburban Hospital/Johns Hopkins Medicine.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NXL:
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- 3 Penny Stocks to Watch Now, 10/9/25
- Why Is Nexalin Technology Stock (NXL) Down 20% Today?
- Nexalin Technology announces additional results in AD with Gen-2 SYNC device
- Nexalin Technology announces issuance of U.S. patent covering HALO Clarity